Figure 8.

Pharmacological specificity of cannabinoid-mediated protection against paclitaxel-induced mechanical allodynia following drug removal. a. WIN55,212-2 (0.5 mg/kg/day s.c.)-mediated anti-allodynia following drug removal was dominated by CB1 receptor activation. b. The protective effects of AM1710 were blocked by AM630 (3 mg/kg/day s.c.) but not AM251 (3 mg/kg/day s.c.)). *P < 0.05, **P < 0.01, ***P < 0.001 vs. Cremophor-Vehicle, #P < 0.05, ##P < 0.01, ###P < 0.001 vs. Taxol-Vehicle, xP < 0.05, xxP < 0.01, xxxP < 0.001 Taxol-Agonist and Taxol-Agonist + AM251 (3) vs. Taxol-Vehicle, P < 0.05, ⟂⟂P < 0.01, ⟂⟂⟂P < 0.001 vs. Taxol-Agonist, Taxol-Agonist + AM251 (3) and Cremophor-Vehicle, αP < 0.05 Taxol-Agonist + AM630 (3) vs. Cremophor-Vehicle, βP < 0.05, ββP < 0.01, βββP < 0.001 Taxol-Agonist, Taxol-Agonist + AM251 (3), and Taxol-Agonist + AM630 (3) vs. Cremophor-Vehicle, ϕϕP < 0.01 Taxol-Agonist + AM251 (3), and Taxol-Agonist + AM630 (3) vs. Taxol-Agonist and Cremophor-Vehicle, +P < 0.05, ++P < 0.01 vs. Taxol-Agonist, ttP < 0.01 Taxol-Agonist + AM251 (3) and Taxol-Agonist + AM630 (3) vs. Cremophor-Vehicle. Doses are in mg/kg/day s.c. (ANOVA; Dunnett and Tukey post-hoc tests). N = 6–8 per group.

Rahn et al. Molecular Pain 2014 10:27   doi:10.1186/1744-8069-10-27
Download authors' original image